In accordance to this, Sorafenib, a multi-kinase inhibitor, which blocks RTKs and RAF isoforms leading to inactivation of MAPK pathway, and Lenvatinib, an oral inhibitor of RTKs, were the first-line approved drugs for the treatment of advanced HCC [29, 30]. This evidence concerns the gene RAF1 and hepatocellular carcinoma.